Impact of EGFR mutations and KRAS amino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer.

Date publication

janvier 2016

Journal

Future oncology (London, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEAU-FALLER Michèle , Pr FALCOZ Pierre-Emmanuel , Dr GUENOT Dominique , Dr GUERIN Eric , Dr MENNECIER Bertrand , Pr MEYER Nicolas , Pr NOEL Georges

Tous les auteurs :
Renaud S, Schaeffer M, Voegeli AC, Legrain M, Guérin E, Meyer N, Mennecier B, Quoix E, Falcoz PE, Guénot D, Massard G, Noël G, Beau-Faller M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26616848

Résumé

Our study aimed to evaluate response rate (RR) to brain metastasis radiotherapy (RT), depending on the genomic status of non-small-cell lung cancer.

Mots clés

Adult, Aged, Aged, 80 and over, Amino Acid Substitution, genetics, Brain Neoplasms, genetics, Carcinoma, Non-Small-Cell Lung, genetics, Disease-Free Survival, Female, Genetic Association Studies, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Mutation, Polymorphism, Single Nucleotide, Proto-Oncogene Proteins p21(ras), genetics, Radiation Tolerance, genetics, Receptor, Epidermal Growth Factor, genetics

Référence

Future Oncol. 2016 Jan;12(1):59-70